TECH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Bio-Techne Corp (TECH) is not a strong buy at the moment for a beginner investor with a long-term strategy. While the stock shows some positive financial performance and potential for moderate growth, the lack of strong technical signals, hedge fund selling, and mixed analyst sentiment suggest holding off on immediate investment.
The MACD is positive but contracting, suggesting weakening momentum. RSI is neutral at 25.751, and moving averages are converging, indicating no clear trend. The stock is trading near its support level (S1: 52.796), with resistance levels at R1: 61.46 and R2: 64.136. Overall, the technical indicators do not strongly support a buy decision.
The company's net income and EPS have increased YoY in Q2 2026, showing profitability growth. Analysts from UBS, TD Cowen, and Citi have raised their price targets, indicating some long-term optimism.
Hedge funds are aggressively selling the stock, with a 5004.01% increase in selling activity last quarter. Gross margin has declined YoY, and revenue has slightly decreased. Analyst sentiment is mixed, with some downgrades and lowered price targets. No recent news or significant positive developments have been reported.
In Q2 2026, revenue dropped slightly by -0.39% YoY to $295.88M. However, net income increased by 8.93% YoY to $38.00M, and EPS rose by 9.09% YoY to 0.24. Gross margin declined to 65.29%, down -1.43% YoY, indicating some pressure on profitability.
Analyst sentiment is mixed. Recent updates include Evercore ISI lowering the price target to $54 and maintaining an In Line rating, while UBS, TD Cowen, and Citi raised their price targets to $79, $80, and $80, respectively, with Buy ratings. Stifel and Baird remain neutral or hold, citing near-term headwinds and flattish growth.
